PMID- 28192720
OWN - NLM
STAT- MEDLINE
DCOM- 20180301
LR  - 20220330
IS  - 1879-0372 (Electronic)
IS  - 0952-7915 (Print)
IS  - 0952-7915 (Linking)
VI  - 45
DP  - 2017 Apr
TI  - Dendritic cells in cancer: the role revisited.
PG  - 43-51
LID - S0952-7915(17)30007-9 [pii]
LID - 10.1016/j.coi.2017.01.002 [doi]
AB  - Dendritic cells (DCs) with their potent antigen presenting ability are long 
      considered as critical factor in antitumor immunity. Despite high potential in 
      promoting antitumor responses, tumor-associated DCs are largely defective in 
      their functional activity and can contribute to immune suppression in cancer. In 
      recent years existence of immune suppressive regulatory DCs in tumor 
      microenvironment was described. Monocytic myeloid derived suppressor cells 
      (M-MDSCs) can contribute to the pool of tumor associated DCs by differentiating 
      to inflammatory DCs (inf-DCs), which appear to have specific phenotype and is 
      critical component of antitumor response. Here we examine the role of inf-DCs 
      along with other DC subsets in the regulation of immune responses in cancer. 
      These novel data expand our view on the role of DCs in cancer and may provide new 
      targets for immunotherapy.
CI  - Copyright (c) 2017 Elsevier Ltd. All rights reserved.
FAU - Veglia, Filippo
AU  - Veglia F
AD  - The Wistar Institute, Philadelphia, PA, 19104, USA.
FAU - Gabrilovich, Dmitry I
AU  - Gabrilovich DI
AD  - The Wistar Institute, Philadelphia, PA, 19104, USA. Electronic address: 
      dgabrilovich@wistar.org.
LA  - eng
GR  - P30 CA010815/CA/NCI NIH HHS/United States
GR  - R01 CA165065/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20170210
PL  - England
TA  - Curr Opin Immunol
JT  - Current opinion in immunology
JID - 8900118
SB  - IM
CIN - J Immunother Cancer. 2018 Jun 20;6(1):60. PMID: 29921314
MH  - Animals
MH  - Dendritic Cells/*immunology/pathology
MH  - Humans
MH  - Immunotherapy
MH  - Myeloid-Derived Suppressor Cells/*immunology/pathology
MH  - Neoplasms/*immunology/pathology/therapy
PMC - PMC5449252
MID - NIHMS848223
EDAT- 2017/02/14 06:00
MHDA- 2018/03/02 06:00
PMCR- 2018/04/01
CRDT- 2017/02/14 06:00
PHST- 2016/10/17 00:00 [received]
PHST- 2016/12/23 00:00 [revised]
PHST- 2017/01/19 00:00 [accepted]
PHST- 2017/02/14 06:00 [pubmed]
PHST- 2018/03/02 06:00 [medline]
PHST- 2017/02/14 06:00 [entrez]
PHST- 2018/04/01 00:00 [pmc-release]
AID - S0952-7915(17)30007-9 [pii]
AID - 10.1016/j.coi.2017.01.002 [doi]
PST - ppublish
SO  - Curr Opin Immunol. 2017 Apr;45:43-51. doi: 10.1016/j.coi.2017.01.002. Epub 2017 
      Feb 10.